Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 6Active not recruiting 2Withdrawn 1Recruiting 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Gastrointestinal Stromal Tumors 2

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × ripretinib × Clear all
NCT03673501 2026-02-05

INTRIGUE

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
453 enrolled 20 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05734105 2025-12-17

INSIGHT

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
54 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡